期刊文献+

仔猪痢清口服液对小鼠的亚慢性毒性试验 被引量:1

Subchronic Toxicity Test of Zizhuliqing Oral Liquid on Mouse
下载PDF
导出
摘要 根据农业部《兽药试验技术规范汇编》观察了仔猪痢清口服液对小白鼠的亚慢性毒性,试验组分设高、中、低3个剂量组,另设空白对照组,连续给药28 d后剖杀各组小鼠。统计学分析结果表明,各组间的体重变化和脏器系数比较无显著差异;各试验组的血常规检测指标、血液生化学检测指标的测定结果与空白对照组测定结果相比差异均不显著;组织病理学检查显示小鼠的主要内脏器官未见明显异常变化。试验结果表明仔猪痢清口服液按临床剂量使用无毒性反应,应用安全可靠。 To study the subchronic toxicity of the Zizhuliqing oral liquid, the test was conducted in accordance with the animal drug technological specification compile of Ministry of Agriculture. Experiment mouse were divide into 4 groups, the 3 experiment groups were given Zizhuliqing oral liquid by oral gavage for 28 days at dose levels of 0.01 mL/g.body, 0.02 mL/g.body, 0.04 mUg.body weight per day. The control group was given saline. Results showed that the body weight, organ coefficient, the index of hematology and blood biochemistry were not signifi- cantly different from that in the control group (p 〉0.05). In addition, results of histopathology examination showed that no obvious abnormalities in the major organ of mice were found among experimental groups after administra- tion of the Zizhuliqing oral liquid. Therefore, our study suggested that the Zizhuliqing oral liquid had no subchronic toxicity and could be safely used for experimental animals.
出处 《基因组学与应用生物学》 CAS CSCD 北大核心 2013年第6期725-728,共4页 Genomics and Applied Biology
基金 江苏省泰州市科技发展计划项目(2013) 江苏牧院2012年院级课题(QN1204)共同资助
关键词 仔猪痢清口服液 小鼠 亚慢性毒性试验 Zizhuliqing oral liquid, Mouse, Subchronic toxicity test
  • 相关文献

参考文献4

二级参考文献54

  • 1陈翠珍,房海.病原大肠埃希氏杆菌对常用抗菌类药物的耐药性测定与分析[J].畜牧兽医杂志,1989(4):25-29. 被引量:2
  • 2蒋雷,费鲜明,苏芳,屠静,周永列.血清球蛋白与慢性丙型肝炎关系的临床研究[J].浙江实用医学,2006,11(5):307-307. 被引量:2
  • 3Wanda M. Haschek. Handbook of Toxicological Pathology [M] . Second Edition, Two-Volume Set, Volume 1-2, 2001: 1266-1335.
  • 4孙家志.三种检测血清ALT方法比较.医学检验与临床,2009,01:95-95.
  • 5Amacher DE. Serum transaminase elevations as indicators of hepatic injuries following the administration of drugs [J] . Regul Toxicol Pharmacol, 1998, 27:119- 130.
  • 6Kaplowitz N. Drug-induced liver disorders: implication for drug development and regulation. [J]. Drug Saf, 2001, 24: 483-490.
  • 7Health Canada Scientific Advisory Panel on Hepatotoxicity. Draft Recommendations from the Scientific Advisory Panel Sub-groups on Hepatotoxicity[N/OL] . Hepatotoxicity of Health Products. Ottawa, Canada: Health Canada;2004. Available at: http://www. hc-sc.gc. ca/hpfb-dgpsa/ tpddpt/sap_ h _ 2004-07-26 _ dp v6 e. html. Accessed July 11, 2005.
  • 8EMEA. Concept Paper on the Development of a Committee for Medicinal Products for Human Use (CHMP) Guideline on Detection of Early Signals for Hepatotoxicity.from Non-Clinical Documentation[N/OL].2004. London, UK: European Agency for the Evaluation of Medicinal Products. Available at: http: //www. emea. eu. int/pdfs/human/ swp/001004en.pdf. Accessed July 11, 2005.
  • 9Weingand K, Brown G, Hall R, et al. Harmonization of animal clinical pathology testing in toxicity and safety studies[J]. Fundam Appl Toxicol, 1996, 29: 198-201.
  • 10Dufour D R, Lott J A, Nolte FS, et al. Diagnosis and monitoring of hepatic injury [J] . performance characteristics of laboratory tests.Clin Chem, 2000, 46:2027- 2049.

共引文献32

同被引文献3

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部